AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05124795
Drug: IMU-935
RxNorm normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMU-935 capsules
Trial: NCT06526624
Drug: HS-20093
RxNorm normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in experimental arm will be given HS-20093 intravenously at a dose of 8.0 mg/kg every 3 weeks, until disease progression or until other criteria for treatment discontinuation are met.
Trial: NCT06247839
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COMP360 (Brand name of psilocybin to be used)
Trial: NCT05935202
Drug: Mitapivat sulfate
RxNorm normalized name: Mitapivat Sulfate
DrugBank: Mitapivat (DB16236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects enrolled Maximum dose: will receive Mitapivat during 56 weeks Starting dose: 50 mg BD Maximum dose: 100 mg BD
Trial: NCT06139302
Drug: BI 1015550
RxNorm normalized name: BI-1015550
DrugBank: Nerandomilast (DB18237)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1015550
Trial: NCT06582186
Drug: Individualization of first voriconazole maintenance doses
RxNorm normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualization of first voriconazole maintenance doses
Trial: NCT05722561
Drug: Nicotine Replacement Product
RxNorm normalized name: nicotine Inhalant Product
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination nicotine replacement therapy with lozenges and patches. Participants are recommended to use the NRT according to product directions.
Trial: NCT06751290
Drug: Cyproheptadine
RxNorm normalized name: Cyproheptadine
DrugBank: Cyproheptadine (DB00434)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Initiation of Cyproheptadine at 0.25mg/kg once daily by mouth at bedtime and titration up to at most three times daily as per participant's primary gastroenterologist.
Trial: NCT06750302
Drug: Methoxyflurane - Penthrox
RxNorm normalized name: Methoxyflurane
DrugBank: Methoxyflurane (DB01028)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3ml
Trial: NCT06751134
Drug: Chimeric Natural Killer Receptor Universal T-cells (CNK-UT)
RxNorm normalized name: B7-H3-specific chimeric antigen receptor T cells
DrugBank: B7-H3-specific chimeric antigen receptor T cells (DB18567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OUTLINE: This is a dose-escalation study of CNK-UT cells followed by a dose-expansion study.~1. Dose Escalation (Single Ascending Dose Study, SAD): During SAD study stage, the participants will be intravenous infused with CNK-UT cells (3\~34×10\^7 CNK+ cells/kg)with a3 +3 design to determine the maximum tolerated dose. During single ascending dose (SAD) study stage, the participants will receive a single dose of CNK-UT cells before the DLT observation period (21 days). If the participants do not experience DLT, they will be able to enter a multiple ascending dose (MAD) study stage.~2. Dose Expansion (multiple ascending dose study, MAD): During MAD study stage, the participants will receive multiple doses of CNK-UT cells. The dosage and frequency of drug administration in the dose expansion stage can be adjusted and determined according to the SAD study.
Trial: NCT06749834
Drug: Intravenous thrombolysis
RxNorm normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive standard dose intravenous alteplase (0.9 mg/kg, the first 10% administered as an initial bolus and the remainder over a 1-hour period, with a maximum dose of 90 mg)，intravenous Tenecteplase(0.25mg/kg，administered as a single intravenous bolus injection over 5 - 10 seconds，with a maximum dose of 25 mg), intravenous reteplase (a bolus of 18 mg followed by a second bolus of 18 mg after 30 minutes) and intravenous prourokinase (rhPro-UK) (15 mg bolus followed by a 20 mg infusion over 30 minutes).
Trial: NCT06418347
Drug: Alpha lipoic acid
RxNorm normalized name: Alpha lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA), also known as 1,2-dithiolane-3-pentanoic acid or thioctic acid, is found in the mitochondria. It acts as an enzymatic cofactor for various enzymes in the Kreb's cycle. ALA has many beneficial properties making it a potential candidate for various clinical disorders. It is considered the universal or ideal antioxidant as it is both water-soluble and fat-soluble facilitating its passage across membran. ALA has direct as well as indirect anti-inflammatory effects. Being a potent antioxidant leads to a reduction in oxidative stress which in turn reduces inflammation, meaning ALA indirectly has anti-inflammatory effects. To add to ALA's benefits, it has anti-inflammatory properties that are independent of its antioxidant effects.
Trial: NCT06418347
Drug: Letrozole
RxNorm normalized name: Letrozole
DrugBank: Letrozole (DB01006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Letrozole is an aromatase inhibitor that controls the conversion of androgen to estrogen and increases ovarian androgens. The administration of letrozole in the follicular phase removes the effect of negative estrogen feedback on the pituitary and hypothalamus, thus increasing the gonadotropins\]. When Letrozole blocks estrogen production, it encourages the body to produce more follicle-stimulating hormone (FSH).The additional FSH stimulates egg development and increases the likelihood of ovulation. Kar, S. Found that letrozole has excellent pregnancy rates compared to clomiphene citrate, Letrozole should be considered at par with clomiphene citrate as first-line drug for ovulation induction in infertile PCOS women.
Trial: NCT04828174
Drug: anti-TRBC1 CAR-T cell therapy
RxNorm normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRBC1 positve patients with relapsed or refractory T cell malignacy will receive CAR-T cell therapy targetting TRBC1
Trial: NCT06740825
Drug: Quizartinib
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Single oral dose of 60 mg
Trial: NCT06740825
Drug: Rufinamide
RxNorm normalized name: Rufinamide
DrugBank: Rufinamide (DB06201)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Twice daily (BID) dose of 400 mg on Days 1 through 32
Trial: NCT05237492
Drug: Tramadol
RxNorm normalized name: Tramadol
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Blood samples will be drawn from 15 patients. Tramadol will be added to all this samples in-vitro and its influence on platelets´ function will be measured.
Trial: NCT06792253
Drug: Ifupinostat Hydrochloride for Injection
RxNorm normalized name: colestipol hydrochloride Granules for Oral Suspension
DrugBank: Colestipol (DB00375)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifupinostat Hydrochloride for Injection,dosage of administration:18.5mg/m\^2,frequency and duration of administration:Medication is administered on days 1, 3, 5, 8, 10, and 12 of each cycle,with a 21-day or 42-day cycle duration.
Trial: NCT06792253
Drug: Rituximab Injection
RxNorm normalized name: rituximab Injection
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab Injection,dosage of administration:375 mg/m\^2,frequency and duration of administration:Medication is administered on day 1 of each cycle or every third cycle, with a 21-day cycle duration.
Trial: NCT06792253
Drug: Gemcitabine Hydrochloride for Injection
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine Hydrochloride for Injection,dosage of administration:1g/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Trial: NCT06792253
Drug: Oxaliplatin Injection
RxNorm normalized name: oxaliplatin Injection
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxaliplatin Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Trial: NCT06792253
Drug: Etoposide Injection
RxNorm normalized name: etoposide Injection
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide Injection,dosage of administration:100mg/m\^2,frequency and duration of administration:Medication is administered on days 1,2,and 3 of each cycle, with a 21-day cycle duration.
Trial: NCT06792253
Drug: Ifosfamide for Injection
RxNorm normalized name: Ifosfamide for Injection
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ifosfamide for Injection,dosage of administration:5000mg/m\^2,frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Trial: NCT06792253
Drug: Carboplatin Injection
RxNorm normalized name: Carboplatin Injection
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carboplatin Injection,,dosage of administration:single dose ≤800 mg (calculated based on AUC=5),frequency and duration of administration:Medication is administered on day 2 of each cycle, with a 21-day cycle duration.
Trial: NCT06739551
Drug: Acitretin
RxNorm normalized name: Acitretin
DrugBank: Acitretin (DB00459)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral acitretin 50 mg once daily for 12 weeks
Trial: NCT05411146
Drug: [14C]-etrumadenant
DrugBank: Etrumadenant (DB17506)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT06736938
Drug: Propofol 1%
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1% is infused intravenously, initially at a bolus dose of 0.5 mg/kg followed by a maintenance dose in a continuous infusion of 0.5-1.0 mg/kg/hour.
Trial: NCT06736938
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam is administered intravenously at an initial dose of 2 mg, as a bolus, followed by aliquots of 0.5 mg or 1 mg.
Trial: NCT06736938
Drug: Pethidine
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pethidine (100 mg/2 ml) is administered intravenously at a dosage of 0.5 mg/kg.
Trial: NCT05726786
Drug: Immunonutrition
RxNorm normalized name: Ensure Surgery Immunonutrition Vanilla
DrugBank: Vanilla (DB10576)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunonutrition: Oral Impact®, Nestlé Health Science, Switzerland.~IN will be administered as per manufacturer suggestion, i.e. three times a day during 7 days preoperatively. Oral Impact® is a powdered oral feed that provides 309 kcal/bag
Trial: NCT06793514
Drug: Probiotic
RxNorm normalized name: PROBIOTIC
DrugBank: Lactobacillus acidophilus (DB15823)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The experimental group will receive the oral probiotics (Lactobacillus casei, Lactobacillus rhamnosus, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium breve, Bifidobacterium infantis, Streptococcus thermophiles) alongside with fructooligosaccharide (FOS), which is prepared in the concentration of 109 cfu by Bisot Khimr and is in the form of an edible sachet that can be dissolved in cold water, which is consumed once a day for one month. Sachets should be stored at a temperature of 2 to 8 degrees Celsius (in the refrigerator), which increases the useful life of probiotic bacteria and makes them more effective.
Trial: NCT06124417
Drug: Sertraline
RxNorm normalized name: Sertraline
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose ranged from 25 to 50 mg, taken orally once daily, and the dosage was adjusted based on the patient's response to the medication.
Trial: NCT04812808
Drug: Bazedoxifene 20 mg
RxNorm normalized name: bazedoxifene 20 MG
DrugBank: Bazedoxifene (DB06401)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bazedoxifene will be administered during the duration of the study in the experimental arm together with chemotherapy.~Prophylactic rivaroxaban (Xarelto®) 10 mg per day orally will be added to avoid thromboembolic events.
Trial: NCT05224609
Drug: Lorlatinib
RxNorm normalized name: LORLATINIB
DrugBank: Lorlatinib (DB12130)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single 100mg oral dose anti-cancer agent
Trial: NCT05567510
Drug: BMS-986369
RxNorm normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Specified dose on specified days
Trial: NCT05291338
Drug: Lipiodol
RxNorm normalized name: Lipiodol
DrugBank: Ethiodized oil (DB00965)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lipiodol dose should be over 5 ml if tumor diameter is less than 5 cm, and the maximum dose will be 10 ml when the tumor develops to more than 5 cm in diameter.
Trial: NCT06789016
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: administration of 0.5ml/kg of 0.2% ropivacaine with 0.1ug/kg Dexmedetomidine for the erector spine plane block
Trial: NCT06789016
Drug: 0.9%NaCl
RxNorm normalized name: triamcinolone acet/0.9%NaCl/PF 40 mg/mL INJECTION VIAL (ML)
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of 0.5ml/kg of 0,2% ropivacaine + 0.01ml/kg 0.9% sodium chloride for the erector spine plane block
Trial: NCT04782258
Drug: Tolvaptan Suspension
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan suspension will be administered orally or via feeding/nasogastric tube at doses of 0.15 mg/kg once daily in the AM, 0.30 mg/kg once daily in the AM, 0.5 mg/kg once daily in the AM, 0.75 mg/kg split dose (0.5 mg/kg AM and 0.25 mg/kg 8 hours later), and 1 mg/kg split dose (0.67 mg/kg AM and 0.33 mg/kg 8 hours later) based on age.
Trial: NCT04782258
Drug: Tolvaptan Tablets
RxNorm normalized name: Tolvaptan Tablets
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan (OPC-41061) Tolvaptan tablets will be administered orally as split-dose regimens (15/7.5 mg, 30/15 mg, and 45/15 mg) upon awakening and 8 hours later (twice daily) based on weight if able to swallow tablets.
Trial: NCT06471361
Drug: Zilucoplan
RxNorm normalized name: Zilucoplan
DrugBank: Zilucoplan (DB15636)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zilucoplan will be self-administered subcutaneously by study participants at pre-specified time points.
Trial: NCT05503797
Drug: Plixorafenib
RxNorm normalized name: Lifirafenib
DrugBank: Lifirafenib (DB14773)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablets
Trial: NCT05503797
Drug: Cobicistat
RxNorm normalized name: Cobicistat
DrugBank: Cobicistat (DB09065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral tablets
Trial: NCT05120505
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The patients in this group will be obtain Metformin starting from 50mg everyday at night, and gradually increase to maximum tolerable dose of 1-2g per day according to weights of patients for 6 months.
Trial: NCT06745076
Drug: Dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06745076
Drug: Vinblastine
RxNorm normalized name: Vinblastine
DrugBank: Vinblastine (DB00570)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04816071
Drug: Essential amino acids
RxNorm normalized name: essential amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary Supplement
Trial: NCT05933044
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Chemoradiotherapy plus durvalumab
Trial: NCT06372574
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tocilizumab 8 mg/kg IV will be administered to patients when necessary to treat potential cytokine release syndrome (CRS), as described in the protocol.
Trial: NCT05803382
Drug: BET Bromodomain Inhibitor ZEN-3694
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05188664
Drug: LM-302
RxNorm normalized name: LM-030
DrugBank: LM-030 (DB18283)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LM-302 is given by intravenous (IV) infusion on day 1 every 3 weeks。
Trial: NCT05188664
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab with a fixed dose is given by intravenous (IV) infusion on day 1 every 3 weeks.
Trial: NCT04931979
Drug: Pembrolizumab Injection [Keytruda]
RxNorm normalized name: pembrolizumab Injection [Keytruda]
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Up to 17 cycles of pembrolizumab until disease progression, toxicity, death, or withdrawal of IC (whichever occurs first)
Trial: NCT05155332
Drug: BI 1831169
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 1831169
Trial: NCT05155332
Drug: anti-PD-1 antibody
RxNorm normalized name: Monoclonal antibody anti-SSEA-1
DrugBank: Fanolesomab (DB14211)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-PD-1 antibody
Trial: NCT04774380
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive durvalumab via IV infusion on Day 1 of each cycle.
Trial: NCT04774380
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive cisplatin via IV administration on Day 1 of each cycle.
Trial: NCT04774380
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive carboplatin via IV administration Day 1 of each cycle.
Trial: NCT04774380
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive etoposide via IV administration on days 1 to 3 of each cycle.
Trial: NCT05751343
Drug: TACE-HACI, plus atezolizumab-bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: transartery chemoembolization and artery infusion of FOLFOX, simultaneously followed by intravenous atezolizumab plus bevacizumab
Trial: NCT06201611
Drug: Nebivolol+ Standard care arm
DrugBank: Nebivolol (DB04861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: This arm will receive tablet Nebivolol 2.5 mg OD uptitrated at 2 weeks to 5 mg and at 4 weeks if well tolerated to 10 mg/day which the participant will continue upto week 24
Trial: NCT06201611
Drug: Epalrestat + Alpha Lipoic Acid +Standard care
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This arm will receive tablet Epalrestat -150mg OD+ cap Alpha Lipoic Acid 600mg OD for 24 weeks.
Trial: NCT04952129
Drug: Selenomethionine
RxNorm normalized name: selenomethionine
DrugBank: Selenomethionine (DB11142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Seleno-amino acid
Trial: NCT04952129
Drug: Methylselenocysteine
RxNorm normalized name: methylselenocysteine
DrugBank: Methylselenocysteine (DB12697)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seleno-amino acid
Trial: NCT03260972
Drug: Chloroprocaine Hcl 2% Inj
RxNorm normalized name: CHLOROPROCAINE HCL 2% INJ
DrugBank: Procaine (DB00721)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
Trial: NCT05564130
Drug: Sodium bicarbonate
RxNorm normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium bicarbonate 1 mmol/ml
Trial: NCT05564130
Drug: Sodium chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium chloride 9 mg/mL
Trial: NCT06090669
Drug: imatinib
RxNorm normalized name: Imatinib
DrugBank: Imatinib (DB00619)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imatinib at 100-400 mg PO QD based on arm assignment/dose level
Trial: NCT06343402
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive IV pembrolizumab
Trial: NCT05613842
Drug: Copper-64 labelled SAR-Bombesin
DrugBank: Copper (DB09130)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiolabeled antagonist analog of bombesin for the diagnosis and treatment of gastrin releasing peptide receptor (GRPR)-positive tumors in adults. The product is Copper-64 labelled SAR-Bombesin (Cu-SAR-BBN). Cu-SAR-BBN uses radioactive forms (radionuclide) of copper, copper-64 (64Cu) to image cancers using Positron Emission Tomography (PET) and then copper-67 (67Cu) for therapy by internal beta radiation. 64Cu-SAR-BBN has 3 basic components; the radionuclide (64Cu), bound via MeCOSar (a bifunctional metal chelator, SAR) to a bombesin analog that targets GRPR.
Trial: NCT06325605
Drug: Bifidobacterium
RxNorm normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 capsules, 3 times a day, for 8 consecutive weeks
Trial: NCT06325605
Drug: Escitalopram Oxalate
RxNorm normalized name: Escitalopram Oxalate
DrugBank: Escitalopram (DB01175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral escitalopram oxalate. The initial dose was 5mg/d, for 7 consecutive days. The dose was increased to 10 mg/d according to the tolerance of the patients for another 7 consecutive days, and then to 20 mg/d according to the patient's condition and tolerance for 8 weeks
Trial: NCT05751941
Drug: Abiraterone
RxNorm normalized name: ABIRATERONE
DrugBank: Abiraterone (DB05812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg of Abiraterone will be given orally daily plus prednisone 5-10 mg daily